| Patent application number | Description | Published |
|---|
| 20090131379 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING - The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes. | 05-21-2009 |
| 20100016611 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS - The invention discloses compounds of formula II: | 01-21-2010 |
| 20100222358 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES - Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein. | 09-02-2010 |
| 20100278905 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER - An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 11-04-2010 |
| 20100280031 | LIPID FORMULATION OF APOPTOSIS PROMOTER - An orally deliverable pharmaceutical composition comprises a drug-carrier system having a Bcl-2 family protein inhibitory compound, e.g., ABT-263, in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 11-04-2010 |
| 20100297194 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER - An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis-HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier; wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 11-25-2010 |
| 20110190540 | Methods for Preparing S1P Receptor Agonists and Antagonists - Disclosed herein are methods of making compounds which are agonists or antagonists of one or more of the individual receptors of the S1P receptor family. | 08-04-2011 |
